PDE4B

Class

Selective oral PDE4B inhibitor

PDE4B (phosphodiesterase 4B) is an enzyme that breaks down cyclic AMP (cAMP), a small signaling molecule that cells use to relay instructions from outside receptors to internal machinery. In immune and inflammatory cells, high cAMP levels generally dampen activation, so degrading it removes a brake on inflammation. PDE4B is one of four related PDE4 subtypes (A, B, C, D) expressed in different tissues; it is particularly abundant in inflammatory cells such as monocytes and neutrophils. Inhibiting PDE4B allows cAMP to accumulate, which suppresses the release of inflammatory mediators and reduces immune cell activity. This mechanism is broadly relevant to chronic inflammatory diseases where excessive immune signaling drives tissue damage, including conditions affecting the skin, joints, and airways. Because PDE4 enzymes are found throughout the body, older non-selective inhibitors of this enzyme family were associated with gastrointestinal side effects and nausea, largely attributed to a related subtype, PDE4D, expressed in the brainstem. Designing compounds that preferentially inhibit PDE4B over PDE4D is intended to preserve anti-inflammatory benefit while reducing these unwanted effects, an approach reflected in selective oral inhibitors developed for inflammatory disease.